Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline in APOE4 Carriers for Pre-symptomatic Alzheimer's Disease
NCT05880849Phase 1Completed
- Sponsor
- Paul E. Schulz
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of choline in Alzheimer's disease (AD), sponsored by Paul E. Schulz. Primary endpoints: Fatty Acid Desaturation Index at 6 months and Phosphatidylcholine at 6 months. Started Jun 2023; status: completed.
02
Drugs
choline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05880849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05880849.